Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that its CEO and managing director, Jennifer Chow, has given notice of her resignation.
The company said that during her tenure, Ms Chow had "built out" its portfolio of novel cell therapy assets, advanced the pipeline from early-stage development to the clinic and managed its operations.
Executive Chairman Paul Hopper said, “Jenn was instrumental in building the Company from a single technology business based on the City of Hope CLTX brain cancer program up until today, where we now have three platform technologies across multiple Phase 1A and Phase 1b clinical trials. The Board acknowledges the major contributions made by Jenn and wishes her well in all future endeavours.”
Chimeric said it will announce further changes to its executive team in the short term.